Navigation Links
Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements regarding anticipated presentations of data relating to Kosan's product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward- looking statements, including, among others, the risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2006 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

NOTE: Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

CONTACT: Jane Green, VP, Corporate Communications of Kosan BiosciencesIncorporated, +1-510-731-5335, or mobile, +1-415-652-4819, or green@kosan.com

Web site: http://www.kosan.com/

Ticker Symbol: (NASDAQ-NMS:KOSN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
(Date:5/15/2008)...5 /- Cytopia Limited,(ASX: ...oming oral,presentation on CYT997 at the 2008 Annu...ology (ASCO) will be accessible to the public via ... Thursday 15 May (US EDT)., The oral presentation...cytotoxic and vascular disrupting agent, in patien...
(Date:5/15/2008)...- Sanofi-aventis,(EURONEXT:...from the,landmark ATHENA study showed Multaq(R) (d... of patients with atrial fibrillation or atrial fl...alizations or death from any,cause by a statistica...udy,primary endpoint. The ATHENA results will be p...
(Date:5/15/2008)... -- CenterWatch, a publishing and,information serv...ical,trials, finds that investigative sites are re...ure) systems. More than 75% of respondents to a re...en trained on three or more,EDC systems. In additi...,their EDC training had improved., State of the C...
(Date:5/15/2008)...ice Plan Positions Blue Cross Blue Shield of ...eport from HealthLeaders-In...- HealthLeaders-InterStudy, the,leading provider o...s the,economy continues to stagnate in Michigan, B... equipped of all of its competitors to weather the...
Breaking Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Trial to Test Gene Therapy for Angina in Women 489 1Trial to Test Gene Therapy for Angina in Women 489 2Trial to Test Gene Therapy for Angina in Women 489 3Researchers develop simple method to create natural drug products 248 1Researchers develop simple method to create natural drug products 248 2EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron LLC to Ceradyne Inc for 2469 Million 485 1EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron LLC to Ceradyne Inc for 2469 Million 485 2HealthInsuranceFinders com Launches Video Contest for Young Directors 481 1HealthInsuranceFinders com Launches Video Contest for Young Directors 481 2
(Date:5/16/2008)...Frail Seniors and People With,Disabilities, OAKLA...sands of,homecare workers across the state are out...s to hours of service, wages and benefits,which w...rkers and the,people they serve deeper into povert...eniors and people with disabilities from Schwarzen...
(Date:5/16/2008)...ational HIV Vaccine Awareness Day, May,18, WASHIN... years into the,AIDS epidemic, someone is newly in...nday, May 18, HIV Vaccine Awareness Day, AIDS Acti...Institute of Allergy and Infectious,Disease (NIAID... everyone,to help end the AIDS epidemic by partici...
(Date:5/16/2008)...ntsworth plc (LSE: HNT), "the Group",a leading in...ications,group headquartered in London, released i...roup,s performance in the first quarter 2008 (the ...ollows below., 15 May 2008, ...rim Management Statement, Record net n...
(Date:5/16/2008)...More in 2007, WASHINGTON, May 16 /PRNewswire-USNe...ancer deaths, the National Cancer Institute (NCI) ...n lung cancer research in 2007,according to updat... today., The two other federal agencies with sign...sease Control and Prevention (CDC) and the,Departm...
Breaking Medicine News(10 mins):Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:Lung Cancer Still Lowest in Federal Funding 2
... women suffer from chronic pelvic floor spasm and ...s, a group of Australian researchers report.// The...requency or urgency in urination, painful intercou...tt of the Royal Hospital For Women, Randwick condu...
...dren with cancer have almost a 80% chance of winni... children who were diagnosed for cancer 20 to 30 y...spite braving odds and coming out of cancer, this ...long-term health problems in adulthood. One of t...
...dengue virus appears to be fast engulfing Uttar Pr...d 17 Friday. "Of the 31 dengue-positive cases admi...s 32 affected districts,// 20 were from Lucknow al...sman of the state health department, told IANS. H...
...ly one out of two women with gestational diabetes ...ch released this month by Tulane University resear...women without gestational diabetes have periodonta...issue of the American Journal of Obstetrics and Gy...
Other Medicine News:Health News:Childhood Cancer Survivors May Suffer Health Problems in Adulthood 2
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: